 |
23 Diseases |  |
21 Trials |
|
21 Trials |  |
1283 News |  |
| «12...567891011121314151617» |
- | Imlygic (talimogene laherparepvec) / Amgen, Vectibix (panitumumab) / Amgen
New P1 trial, Tumor mutational burden: Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin (clinicaltrials.gov) - Nov 15, 2019
P1, N=30, Not yet recruiting, Sponsor: Rutgers, The State University of New Jersey
- Imlygic (talimogene laherparepvec) / Amgen
The Role of T-VEC and Other Oncolytic Viruses in Priming the Tumor Microenvironment for Immunotherapy (Cherry Blossom Ballroom) - Oct 30, 2019 - Abstract #SITC2019SITC_1251;
- | Imlygic (talimogene laherparepvec) / Amgen
Clinical, Journal, Combination therapy, Checkpoint inhibition, PD(L)-1 Biomarker, IO Biomarker: Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone. (Pubmed Central) - Oct 29, 2019
Intralesional treatments with immunomodulatory agents such as the oncolytic herpes virus Talimogene Laherparepvec and interleukin-2 (IL-2) have been successfully used in patients with injectable metastases...Our case series supports the concept that patients with initial resistance to PD-1 inhibitor therapy and injectable lesions can profit from an additional intralesional IL-2 therapy which was well tolerated. Response to this therapy is accompanied by increase in AEC and a strong T cell-based inflammatory infiltrate.
- | Imlygic (talimogene laherparepvec) / Amgen, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Journal: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. (Pubmed Central) - Oct 29, 2019
Our data suggest that combining checkpoint inhibitor(s) with T-VEC injection may provide a synergistic efficacy for patients with unresectable melanoma. We observed a better overall response rate and complete response rate compared to published studies on similar therapeutic regimens.
- | Imlygic (talimogene laherparepvec) / Amgen
Review, Journal, Oncolytic virus: The Role of Oncolytic Viruses in the Treatment of Melanoma. (Pubmed Central) - Oct 25, 2019
Talimogene laherparepvec (T-VEC) is the first OV approved for the treatment of melanoma and presents new challenges as it enters the clinical setting...Several OVs and therapeutic combinations are in development. Immunooncolytic virotherapy combined with immune checkpoint inhibitors is promising for the treatment of advanced melanoma.
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC (clinicaltrials.gov) - Oct 21, 2019
P=N/A, N=920, Recruiting, Sponsor: Amgen
Immunooncolytic virotherapy combined with immune checkpoint inhibitors is promising for the treatment of advanced melanoma. Trial completion date: Aug 2024 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2026
- | canerpaturev (TBI-1401) / Takara
Clinical, Journal, Oncolytic Virus: Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. (Pubmed Central) - Oct 18, 2019
Other oncolytic viruses using different parental viruses have also been tested in Phase III clinical trials and are ready for drug approval: Pexa-Vec (pexastimogene devacirepvec), an oncolytic vaccinia virus, CG0070, an oncolytic adenovirus, and REOLYSIN (pelareorep), an oncolytic reovirus...In this review, we summarize clinical trials assessing oncolytic virus therapy that were conducted or are currently ongoing in Japan, specifically, T-VEC, the abovementioned oncolytic herpes simplex virus type 1, G47Δ, a third-generation oncolytic herpes simplex virus type 1, HF10, a naturally attenuated oncolytic herpes simplex virus type 1, Telomelysin, an oncolytic adenovirus, Surv.m-CRA, another oncolytic adenovirus, and Sendai virus particle. In the near future, oncolytic virus therapy may become an important and major treatment option for cancer in Japan.
- | Imlygic (talimogene laherparepvec) / Amgen, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Journal: Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab. (Pubmed Central) - Oct 18, 2019
In the near future, oncolytic virus therapy may become an important and major treatment option for cancer in Japan. This case highlights the complexities of care of patients with coexistent cancers, demonstrates rapid progression of primary cutaneous ALCL on nivolumab and introduces a novel adverse effect of Talimogene laherparepvec.
- | Imlygic (talimogene laherparepvec) / Amgen, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Journal, HEOR, Combination therapy, Monotherapy: Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. (Pubmed Central) - Oct 16, 2019
Combination therapy of talimogene laherparepvec plus ipilimumab does not offer an economically beneficial treatment option relative to ipilimumab monotherapy at the population level. This should not preclude treatment for individual patients for whom this regimen may be indicated.
- | Imlygic (talimogene laherparepvec) / Amgen, Mekinist (trametinib) / Novartis, trametinib
Journal, Oncolytic Virus, PD(L)-1 Biomarker, IO Biomarker: MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. (Pubmed Central) - Oct 13, 2019
Triple therapy with the combination of T-VEC, MEK inhibition, and anti-PD-1 antibody further augmented responses. These data support clinical development of combination oncolytic viruses, MEK inhibitors, and checkpoint blockade in patients with melanoma.
- | Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date, Combination therapy: Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases (clinicaltrials.gov) - Oct 10, 2019
P1b, N=36, Recruiting, Sponsor: Amgen
These data support clinical development of combination oncolytic viruses, MEK inhibitors, and checkpoint blockade in patients with melanoma. Trial primary completion date: Jun 2020 --> Dec 2020
- Opdivo (nivolumab) / Ono Pharma, BMS
An oncolytic adenovirus mediated by PD-1 antibody for cancer therapy () - Oct 4, 2019 - Abstract #CRICIMTEATIAACR2019CRI-CIMT-EATI-AACR_6;
Meanwhile, the viability of tumor cells treated with AdC68-sp/E1A-nivolumab descended poignantly in a mechanism of virus-induced apoptosis through activating the p53 signaling pathway and cell cycle retardation of cancer cells. Further study in immunocompetent and immunodeficient mouse models is underway to evaluate the synergistic anti-tumor efficacy and mechanism in vivo.
- Imlygic (talimogene laherparepvec) / Amgen
Is intracellular STING expression a biomarker for oncolytic herpes virus immunotherapy? (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_1005;
Intracellular STING was inversely associated with T-VEC-mediated lysis and suggests that STING may be a predictive biomarker for T-VEC responses. These data also support a role for T-VEC in restoring host immune responses in STING-deficient melanoma.
- Imlygic (talimogene laherparepvec) / Amgen, Mekinist (trametinib) / Novartis
MEK inhibition enhances oncolytic herpes virus immunotherapy (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_882;
Oncolytic virus immunotherapy is improved by MEK inhibition and appears to sensitize tumors to immune checkpoint blockade. These studies support clinical translation of this combination approach into the clinic.
- Imlygic (talimogene laherparepvec) / Amgen
A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells plus talimogene laherparepvec (T-VEC) in patients with advanced melanoma (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_819;
These studies support clinical translation of this combination approach into the clinic. IT co-injection of autologous CD1c (BDCA-1)+ myDC with T-VEC is feasible and tolerable and resulted in encouraging early signs of anti-tumor activity in patients with immune checkpoint inhibitor refractory melanoma who received high dose CD1c (BDCA-1)+ myDC.
- Imlygic (talimogene laherparepvec) / Amgen
A randomized phase 2 study of neoadjuvant talimogene laherparepvec (T-VEC) plus surgery vs surgery for resectable stage IIIB-IVM1a melanoma: 2-year primary analysis of recurrence-free survival (RFS) (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_816;
P2
T-cell influx and PD-L1 upregulation after T-VEC treatment support a role for the adaptive immune system consistent with the mechanisms of action. Additional biomarker results including clinical correlations will be presented at the congress.
- Keytruda (pembrolizumab) / Merck (MSD), ONCOS-102 / Targovax
A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma (Prince George's Exhibition Hall C) - Oct 2, 2019 - Abstract #SITC2019SITC_305;
ONCOS-102 combined with pembrolizumab is tolerable and appears to induce systemic and lesional immune activation that can lead to objective responses in anti-PD-1 refractory melanomas. An expansion cohort is currently enrolling pts to receive up to 24 weeks of ONCOS-102 injections.
- | Provecta (rose bengal sodium) / Provectus
Enrollment change, Trial completion date, Trial termination, Oncolytic virus, Metastases: PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma (clinicaltrials.gov) - Oct 2, 2019
P3, N=32, Terminated, Sponsor: Provectus Biopharmaceuticals, Inc.
An expansion cohort is currently enrolling pts to receive up to 24 weeks of ONCOS-102 injections. N=225 --> 32 | Trial completion date: Apr 2019 --> Sep 2019 | Active, not recruiting --> Terminated; Inadequate rate of enrollment
- | Trial primary completion date, Combination therapy, Metastases: Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma (clinicaltrials.gov) - Sep 30, 2019
P1b, N=20, Recruiting, Sponsor: West Cancer Center
N=225 --> 32 | Trial completion date: Apr 2019 --> Sep 2019 | Active, not recruiting --> Terminated; Inadequate rate of enrollment Trial primary completion date: Jun 2019 --> Jun 2020
- |||| Imlygic (talimogene laherparepvec) / Amgen, Yervoy (ipilimumab) / Ono Pharma, BMS
#ESMO19 | @PAscierto: Do we really need to combine T-VEC + ipi? #melsm @jasonlukemd @MandalaMario @istitutotumori @OmidHamidMD @Melanoma_doctor @alexshoushtari @MDAndersonNews @FunchainMD @BernardAFox (Twitter) - Sep 30, 2019
- Imlygic (talimogene laherparepvec) / Amgen, Tecentriq (atezolizumab) / Roche
Solti-1503 prometeo: combination of talimogene laherparepvec (t-vec) with atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy (Hall 1 - Poster Session 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_995;
P1
To date, 4 patients have been included and it is expected to complete the first safety data review in September 2019. The study recruitment is planned to be completed by October 2020.Clinical trial identification: NCT03802604
- Imlygic (talimogene laherparepvec) / Amgen, Tecentriq (atezolizumab) / Roche, Yervoy (ipilimumab) / Ono Pharma, BMS
Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer (Hall 1 - Poster Session 3) - Sep 25, 2019 - Abstract #SABCS2019SABCS_712;
P1b
One confirmed partial response in the TNBC cohort has been seen thus far. Conclusion T-VEC intrahepatic injection in combination with IV atezo at standard doses has thus far been demonstrated as feasible and tolerable with no DLTs observed in the TNBC cohort to date.
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date, Combination therapy, Metastases: TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) (clinicaltrials.gov) - Sep 22, 2019
P1/2, N=15, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
Conclusion T-VEC intrahepatic injection in combination with IV atezo at standard doses has thus far been demonstrated as feasible and tolerable with no DLTs observed in the TNBC cohort to date. Trial completion date: Jun 2020 --> Aug 2024 | Trial primary completion date: Jun 2019 --> Aug 2022
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date: Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Sep 18, 2019
P2, N=112, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jun 2020 --> Aug 2024 | Trial primary completion date: Jun 2019 --> Aug 2022 Trial completion date: Sep 2019 --> Sep 2020
- Imlygic (talimogene laherparepvec) / Amgen, Yervoy (ipilimumab) / Ono Pharma, BMS
Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial (Granada Auditorium (Hall 3)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3710;
P1b/2
PFS was numerically longer with the combo than ipi. Survival is likely confounded by subsequent anticancer therapies (NCT01740297).
- Imlygic (talimogene laherparepvec) / Amgen
Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma (Cordoba Auditorium (Hall 7)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3630;
P2
T-cell influx and PD-L1 upregulation after T-VEC tx support a role for the adaptive immune system consistent with the mechanisms of action. Clinical trial identification: NCT02211131, release date: August 7, 2014; EudraCT: 2014-001146-13.
- Imlygic (talimogene laherparepvec) / Amgen
Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3047;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Imlygic (talimogene laherparepvec) / Amgen
Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3046;
P3
Clinical trial identification: NCT00769704. Legal entity responsible for the study: Amgen Inc.
- Imlygic (talimogene laherparepvec) / Amgen
Re-introduction of T-VEC monotherapy in recurrent stage IIIB/C-IVM1a melanoma is effective (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3045;
This real world data on re-introduction of T-VEC monotherapy in stage IIIB/C-IVM1a melanoma suggests T-VEC could be a treatment option for chronic disease control in this group of patients. Legal entity responsible for the study: The authors.
- Imlygic (talimogene laherparepvec) / Amgen
Effective treatment with T-VEC monotherapy in stage IIIB/C-IVM1a melanoma of the head & neck region (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3044;
This real world data on T-VEC monotherapy in stage IIIB/C-IVM1a unresectable melanoma of the head and neck region demonstrates interesting results and suggests T-VEC is an elegant alternative to systemic therapy in this select elderly and frail patient population. Legal entity responsible for the study: The authors.
- | Imlygic (talimogene laherparepvec) / Amgen, Provenge (sipuleucel-T) / Bausch Health
Review, Journal: Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy. (Pubmed Central) - Sep 11, 2019
Therefore, this review focuses on the mechanisms, advantages, and prospects of OMVs as antigen-carrier vaccines in cancer vaccine development. We believe that OMV-based vaccines present a safe and effective cancer therapeutic option with broad application prospects.
- | Imlygic (talimogene laherparepvec) / Amgen
Journal: ASO Author Reflections: Implementing a Program of Talimogene laherparepvec. (Pubmed Central) - Sep 6, 2019
We believe that OMV-based vaccines present a safe and effective cancer therapeutic option with broad application prospects. No abstract available
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date, Surgery, Metastases: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (clinicaltrials.gov) - Sep 6, 2019
P1, N=21, Recruiting, Sponsor: National Cancer Institute (NCI)
No abstract available Trial completion date: Jul 2019 --> Sep 2020 | Trial primary completion date: Jul 2019 --> Sep 2020
- | Imlygic (talimogene laherparepvec) / Amgen
New P2 trial, Metastases: Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). (clinicaltrials.gov) - Aug 28, 2019
P2, N=100, Not yet recruiting, Sponsor: Amgen
- | Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Tumor mutational burden, IO biomarker, Metastases: S1607: Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov) - Aug 22, 2019
P2, N=64, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2019 --> Sep 2020 | Trial primary completion date: Jul 2019 --> Sep 2020 Trial completion date: Jul 2019 --> Jun 2020 | Trial primary completion date: Jul 2019 --> Jun 2020
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date, IO biomarker, Surgery: Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - Aug 22, 2019
P2, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2019 --> Jun 2020 | Trial primary completion date: Jul 2019 --> Jun 2020 Trial completion date: Aug 2019 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Dec 2020
- | Imlygic (talimogene laherparepvec) / Amgen
New P2 trial: KAPVEC: Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma (clinicaltrials.gov) - Aug 21, 2019
P2, N=20, Not yet recruiting, Sponsor: Assistance Publique - H
- | Imlygic (talimogene laherparepvec) / Amgen
Journal: Correlates of response and outcomes with talimogene laherperpvec. (Pubmed Central) - Aug 21, 2019
Trial completion date: Aug 2019 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Dec 2020 These findings demonstrate that TVEC is an effective and safe treatment for metastatic melanoma in a real-life clinical setting, and suggest parameters to aid in appropriate therapy selection for optimal response.
- | Imlygic (talimogene laherparepvec) / Amgen
Clinical, Observational data, Journal: Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1). (Pubmed Central) - Aug 14, 2019
No herpetic lesions or infections were reported. T-VEC was well tolerated and showed clinical utility.
- | Imlygic (talimogene laherparepvec) / Amgen, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, P2 data, Journal, Combination therapy, IO biomarker: Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. (Pubmed Central) - Aug 7, 2019
Conclusion The study met its primary end point; the objective response rate was significantly higher with talimogene laherparepvec plus ipilimumab versus ipilimumab alone. These data indicate that the combination has greater antitumor activity without additional safety concerns versus ipilimumab.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Immunotherapy in melanoma. (Pubmed Central) - Aug 7, 2019
The role of immunotherapy continues to expand with multiple new agents approved in the adjuvant as well as metastatic setting, as first-line therapy and beyond. We review the currently approved drugs for the treatment of melanoma, along with clinical trial data, adverse side effects, response assessment and future directions.
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date: A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors (clinicaltrials.gov) - Aug 7, 2019
P2, N=34, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
We review the currently approved drugs for the treatment of melanoma, along with clinical trial data, adverse side effects, response assessment and future directions. Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- | Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date: Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma (clinicaltrials.gov) - Aug 7, 2019
P1, N=18, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 Trial primary completion date: Jun 2019 --> Mar 2020
- | Imlygic (talimogene laherparepvec) / Amgen, Opdivo (nivolumab) / BMS
Trial suspension, PD(L)-1 Biomarker, IO biomarker: NCI#10057: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (clinicaltrials.gov) - Aug 6, 2019
P2, N=68, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2019 --> Mar 2020 Recruiting --> Suspended
- | Imlygic (talimogene laherparepvec) / Amgen
Journal, Combination therapy, Checkpoint inhibition: Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. (Pubmed Central) - Jul 26, 2019
...Recently, an oHSV (talimogene laherparepvec) has been approved for the treatment of advanced melanoma...Curative therapy required oHSV expressing IL-12 in combination with two checkpoint inhibitors, anti-PD-1 and anti-CTLA-4. This response required CD4 and CD8 T cells, and macrophages in a complex interplay.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Advances in Immunotherapy of Malignant Melanoma (Pubmed Central) - Jul 24, 2019
10. 2017.
- || Imlygic (talimogene laherparepvec) / Amgen
Talimogene laherparepvec (Twitter) - Jul 17, 2019
- Imlygic (talimogene laherparepvec) / Amgen
Talimogene Laherparepvec in Early Metastatic Melanoma, an elegant alternative to systemic immunotherapy (N101-102) - Jul 16, 2019 - Abstract #EADV2019EADV_833;
- | canerpaturev (TBI-1401) / Takara
Journal, IO Biomarker: Oncolytic herpes simplex virus and immunotherapy. (Pubmed Central) - Jul 13, 2019
We reviewed the immunotherapy mechanism of the oHSV and provided a series of cases. We also pointed out that an in-depth study of the application of oHSV in cancer treatment will potentially benefits cancer patients more.
- | Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Metastases: A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma (clinicaltrials.gov) - Jul 11, 2019
P2, N=60, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
We also pointed out that an in-depth study of the application of oHSV in cancer treatment will potentially benefits cancer patients more. N=26 --> 60